MassBio is collaborating with Novartis to bring the Novartis Partnering Forum to life on July 7. To be hosted on-site at Novartis (181 Massachusetts Ave, Cambridge, MA), the forum is a unique opportunity to bring ambitious and talented people together to explore new horizons, develop ideas, and identify unique opportunities.
What to expect: The Forum will begin with an eye-opening conversation exploring how Biotechs, VCs, and Pharma can partner with impact to achieve impressive outcomes. Focusing on the Boston ecosystem, you’ll hear from:
- Bruce Booth, Partner | Atlas Ventures
- Ronny Gal, Chief Strategy and Growth Officer | Novartis
- Fiona Marshall, President of Biomedical Research| Novartis
- Susanne Kreutz, Global Head of Corporate & Business Development
The conversation will explore four key themes:
- The importance of external innovation to fill the pharma pipeline
- VC perspective on the current financing environment and the role of pharma
- Pharma perspective on flexible deal structures
- Successful partnering examples at Novartis
Getting face-to-face: After the discussion, you are invited to enjoy a networking opportunity to connect with senior Novartis leaders from the Partnering team as well as experts from the Novartis Biomedical Research organization. Experts from each therapeutic area will be able to deep dive into specific themes and issues within each, giving you personalized, first-hand access to the scientists and dealmakers.
Be in the room: This event is intended for senior leaders (biotech CEOs and other C-level biotech executives) of biotechs working in Novartis’ therapeutic areas of focus: cardiovascular, renal, and metabolic, immunology, neuroscience, and oncology. Through the event page, you may add your name to the waitlist for an opportunity to participate.
What they’re saying: “In partnering, there is no ‘one-size-fits-all,’ and our teams are agile and flexible, approaching deal-making in a deal-type agnostic manner. This enables us to tailor each deal to its unique circumstances, aiming to deliver high-value treatments to millions of patients worldwide.”
Why the Novartis Partnering Forum: Novartis believes impactful partnering fuels scientific progress and patient care. They also believe in the power of personal connection and the power of local networks. From their focused R&D engine to high-quality manufacturing and novel access approaches, Novartis has the expertise and capabilities to bring high-value treatments to millions of people around the globe.
What we’re saying: “With the current restricted funding environment, and the need for external innovation to push the boundaries of drug development, this is an incredible opportunity to get inside one of the world’s top pharma companies,” said Jason Cordeiro, MassBio’s Chief Operating and Innovation Officer. “MassBio prides itself on facilitating connections, and we can’t wait to see the collaborations that ignite at this forum.”